Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:01:38 EDT Tue 05 May 2026
Enter Symbol
or Name
USA
CA



Q:CYTK - CYTOKINETICS INC - https://www.cytokinetics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYTK - Q0.265.90·68.000.566.05+2.704.32,149.7130,66919,34163.00  67.05  63.0070.98  29.31May 04May 0415 min RT 2¢

Recent Trades - Last 10 of 19341
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-04 16:00U:CYTKNews ReleaseCytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
2026-04-28 07:30U:CYTKNews ReleaseCytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
2026-04-21 16:00U:CYTKNews ReleaseCytokinetics to Announce First Quarter Results on May 5, 2026
2026-04-20 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-04-06 16:00U:CYTKNews ReleaseCytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
2026-03-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-03-16 08:00U:CYTKNews ReleaseCytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
2026-03-02 16:00U:CYTKNews ReleaseCytokinetics to Participate in March Investor Conferences
2026-02-24 16:00U:CYTKNews ReleaseCytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
2026-02-17 07:30U:CYTKNews ReleaseCytokinetics Announces European Commission Approval of MYQORZO(TM) (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
2026-02-12 16:00U:CYTKNews ReleaseCytokinetics to Announce Fourth Quarter Results on February 24, 2026
2026-02-09 07:30U:CYTKNews ReleaseCytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
2026-01-27 08:00U:CYTKNews ReleaseCytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
2026-01-27 07:30U:CYTKNews ReleaseCytokinetics Announces MYQORZO(TM) (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
2026-01-20 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-05 16:00U:CYTKNews ReleaseCytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-19 16:00U:CYTKNews ReleaseCytokinetics Announces FDA Approval of MYQORZO(TM) (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
2025-12-17 07:30U:CYTKNews ReleaseCytokinetics Announces NMPA Approval of MYQORZO(TM) (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
2025-12-16 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-12-12 08:43U:CYTKNews ReleaseCytokinetics Announces Positive CHMP Opinion of MYQORZO(TM) (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy